Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
暂无分享,去创建一个
L. Sequist | K. O'Byrne | T. Mok | Yi-long Wu | Chun-Ming Tsai | M. Schuler | J. Yang | W. Su | V. Zazulina | N. Yamamoto | V. Hirsh | M. Sebastian | M. Boyer | V. Gorbunova | S. Popat | Caicun Zhou | Jifeng Feng | Shun Lu | K. Lee | J. Bennouna | T. Kato | Cheng-ping Hu | M. Shahidi | Sarayut Lucien Geater | D. Massey | S. Orlov | K. Lee | S. Geater | Yunchao Huang | S. Lu | C. Tsai